LIVALO is a registered trademark of the Kowa group of companies.
Encouraging research and development of new products through employee initiatives and strategic alliances is key to serving and anticipating the changing needs of customers and patients.
LIVALO is a registered trademark of the Kowa group of companies.
Kowa’s Research & Development activities are carried out at the company’s laboratories in Tokyo and Fuji. The focus is on lifestyle-related diseases, immune disorders and allergy, and dermatology and ophthalmology.
Kowa Research Institute is responsible for the United States development of Kowa’s new drug candidates. Kowa has several drugs currently in Phase I or later clinical development, for conditions such as dyslipidemia, type 2 diabetes mellitus and cancer. Please click here for an overview of Kowa’s drug candidates currently in Phase I or later clinical development.
Established in 1894, Kowa Company, Ltd. is actively engaged in various manufacturing and commercial activities in the fields of pharmaceutical, life science, information technology, textiles, machinery and various consumer products.
For more information, please visit the Kowa Company, Ltd. products website.